Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)

Drug Discovery Today

Volumn 12, Issue 17-18, 2007, Pages 740-747

  Ahmed, Mohamed H ^a   Byrne, Christopher D ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

CALORIC RESTRICTION; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; FATTY LIVER; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; PPAR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 34548392209     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.07.009     Document Type: Review

References (34)

1. Ahmed M.H., and Byrne C.D. Non-alcoholic steatohepatitis. In: Byrne C.D., and Wild S.H. (Eds). The Metabolic Syndrome (2005), John Wiley & Sons Ltd. 279-305
2. Ekstedt M., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
3. Adams L.A., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129 (2005) 113-121
4. Ahmed M.H. Biochemical markers: the road map for the diagnosis of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 127 (2007) 20-22
5. Ahmed M.H., and Byrne C.D. Metabolic syndrome, diabetes and cardiovascular risk. In: Packard C.J. (Ed). The Year in Lipid Disorders (2007), Clinical Publishing 3-26
6. Belfort R., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (2006) 2297-2307
7. Promrat K., et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39 (2004) 188-196
8. Horton J.D., et al. Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 5987-5992
9. Shimomura I., et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell 6 (2000) 77-86
10. Kim J.B., et al. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J. Clin. Invest. 101 (1998) 1-9
11. Matsuda M., et al. SREBP cleavage-activating protein (SCAP) is required for increased lipid synthesis in liver induced by cholesterol deprivation and insulin elevation. Genes Dev. 15 (2001) 1206-1216
12. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001) 1167-1174
13. Seppala-Lindroos A., et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol. Metab. 87 (2002) 3023-3028
14. Holt H.B., et al. Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. Diabetologia 49 (2006) 141-148
15. Gastaldelli A., et al. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50 (2001) 1807-1812
16. Roden M., and Bernroider E. Hepatic glucose metabolism in humans-its role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 17 (2003) 365-383
17. Najjar S.M., et al. Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab. 2 (2005) 43-53
18. Puigserver P., et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423 (2003) 550-555
19. Soukas A., et al. Leptin-specific patterns of gene expression in white adipose tissue. Genes Dev. 14 (2000) 963-980
20. Fryer L.G., et al. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277 (2002) 25226-25232
21. Schimmack G., et al. AMP-activated protein kinase: role in metabolism and therapeutic implications. Diabetes Obes. Metab. 8 (2006) 591-602
22. Xu J., et al. Dietary polyunsaturated fats regulate rat liver sterol regulatory element binding proteins-1 and -2 in three distinct stages and by different mechanisms. J. Nutr. 132 (2002) 3333-3339
23. Stoeckman A.K., et al. Mlx is the functional heteromeric partner of the carbohydrate response element-binding protein in glucose regulation of lipogenic enzyme genes. J. Biol. Chem. 279 (2004) 15662-15669
24. He Z., et al. Modulation of carbohydrate response element-binding protein gene expression in 3T3-L1 adipocytes and rat adipose tissue. Am. J. Physiol. Endocrinol. Metab. 287 (2004) E424-E430
25. Grefhorst A., et al. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277 (2002) 34182-34190
26. Foretz M., et al. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 12737-12742
27. Shimano H., et al. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274 (1999) 35832-35839
28. Shimomura I., et al. Nuclear sterol regulatory element-binding proteins activate genes responsible for the entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J. Biol. Chem. 273 (1998) 35299-35306
29. Moon Y.A., and Horton J.D. Identification of two mammalian reductases involved in the two-carbon fatty acyl elongation cascade. J. Biol. Chem. 278 (2003) 7335-7343
30. Li J., et al. Insig-1 "brakes" lipogenesis in adipocytes and inhibits differentiation of preadipocytes. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 9476-9481
31. Takaishi K., et al. Hepatic insig-1 or -2 overexpression reduces lipogenesis in obese Zucker diabetic fatty rats and in fasted/refed normal rats. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 7106-7111
32. Sun L.P., et al. Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J. Biol. Chem. 280 (2005) 26483-26490
33. Reddy J.K. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001) G1333-G1339
34. Cherkaoui-Malki M., et al. Identification of novel peroxisome proliferator-activated receptor alpha (PPARalpha) target genes in mouse liver using cDNA microarray analysis. Gene Expr. 9 (2001) 291-304